Key facts
as of Oct 2026- Developer of a microsphere product designed to improve the treatment of hypervascular tumors.
- ABK Biomedical is valued at approximately $73.0M as of Oct 2026 (last reported valuation).
- It has raised $121.7M across 4 recorded rounds; the latest was Seed Round ($2.6M) in Oct 2025.
- Notable investors include F-Prime Capital, Eight Roads, Invest Nova Scotia, PIC Investment Group, Atlantic Canada Opportunities Agency — 11 tracked in total.
- ABK Biomedical has filed 4 Form Ds with the SEC since 2019, most recently May 2025 ($26.1M sold to 24 investors).
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$73.0M
ABK Biomedical's last reported valuation, Dec 2022. Nothing priced has surfaced since.
Free account
More of ABK Biomedical with a free account
- ·The complete investor list: 11 names
- ·Watch ABK Biomedical: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
4 roundsAbout ABK Biomedical
Developer of a microsphere product designed to improve the treatment of hypervascular tumors. The company's product is a novel radiopaque bland embolic and beta radiation emitting agent that helps to improve the targeting of tumor vascularity and tumor tissue, enabling doctors to help standardize, optimize, and personalize minimally invasive therapies.
- Sector
- Healthcare
- HQ
- Halifax, Canada
- Founded
- 2012
- Employees
- 41
- Website
- abkbiomedical.com/
- Ownership
- Privately Held (backing)